Molecular Partners Ag (MOLN) Other financing activities (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Other financing activities of -$6.39 for Q1 2026, down 43.52% year-over-year from -$11.3 in Q1 2025, and down 100.07% quarter-over-quarter from $8737.0 in Q3 2025.
Molecular Partners Ag (MOLN) Other financing activities (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Other financing activities for 6 consecutive years, with -$6.39 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.39 |
| Mar 31, 2026 | -6.39 |
| Sep 30, 2025 | 8,737.02 |
| Sep 30, 2025 | 8,737.02 |
| Jun 30, 2025 | -8,450.40 |
| Jun 30, 2025 | -8,450.40 |
| Mar 31, 2025 | -4.45 |
| Mar 31, 2025 | -4.45 |
| Sep 30, 2024 | 8,067.91 |
| Sep 30, 2024 | 8,067.91 |
| Jun 30, 2024 | -7,737.24 |
| Jun 30, 2024 | -7,737.24 |
| Mar 31, 2024 | -3.44 |
| Mar 31, 2024 | -3.44 |
| Sep 30, 2023 | -30,535.29 |
| Sep 30, 2023 | -30,535.29 |
| Jun 30, 2023 | 30,026.52 |
| Jun 30, 2023 | 30,026.52 |
| Mar 31, 2023 | 2.16 |
| Mar 31, 2023 | 2.16 |